Tromantadine hydrochloride in the treatment of herpes simplex. Results of a double-blind therapeutic trial and an open prophylactic investigation.
In a randomised, double-blind trial on 20 patients with herpes simplex, tromantadine hydrochloride (TH) ointment had a significant therapeutic effect. No side effects were observed. 12 lesions were treated with the active drug and 13 with placebo. In an open study on 19 patients with recurrent herpes simplex, the prophylactic effect of the drug was good in most patients. During long-term treatment, 2 patients developed eczematous lesions. It is concluded that TH is a valuable topical agent for the treatment of herpes simplex.
D000284:Administration, Oral; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004485:Eczema / Q000139:chemically induced; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D009824:Ointments; D012008:Recurrence; D013997:Time Factors
D000998:Antiviral Agents; D009824:Ointments; D000547:Amantadine; C004279:tromantadine